ONWD.BR Onward Medical EURONEXT intraday 31 Mar 2026: earnings to test EUR 3.32

ONWD.BR stock trades at EUR 3.315 intraday on EURONEXT as investors wait for the 31 Mar 2026 earnings release. The report is scheduled for 15:40 UTC and could move sentiment after a recent share slide: the stock is down 26.55% over three months and has year-to-date losses of 24.37%. Onward Medical N.V. operates in Biotechnology within Healthcare, where clinical readouts and cash runway drive market moves. We preview the numbers, technicals, valuation and what to watch in the report.

Earnings context for ONWD.BR stock

Onward Medical (ONWD.BR) will publish results on 31 Mar 2026 at 15:40 UTC. The report follows a full-year 2025 update highlighting US trial progress and commercial preparation Seeking Alpha. Expectations centre on R&D spend, cash burn and any guidance on ARCEX and ARCIM programmes. With EPS at -0.74 (TTM) and no consensus price target, the earnings release is the primary near-term catalyst for the stock.

Recent financials and company metrics

Onward Medical reported thin revenue per share of EUR 0.03 (TTM) and net income per share of -EUR 0.87 (TTM). Market capitalisation stands at EUR 148,190,750 with 44,635,768 shares outstanding. Key ratios include PE -4.49, PB 5.35, current ratio 4.34 and cash per share EUR 0.92. The company’s operating cash flow per share is negative at -EUR 0.80, underlining reliance on financing or milestones to extend the runway.

Technical picture and trading action

Intraday range is EUR 3.25–3.41 with volume at 141,361, slightly above the average 130,193. Momentum indicators show RSI 24.33 and Williams %R -98.51, flagging oversold conditions. Price averages sit at 50-day EUR 4.15 and 200-day EUR 4.45, both above the current level. Traders should note Bollinger middle band EUR 3.69 and ATR EUR 0.14 for short-term risk sizing.

Meyka AI grade and valuation summary

Meyka AI rates ONWD.BR with a score out of 100: 62.67 / Grade B — HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst signals. Valuation remains challenging: price-to-sales is 117.43 (TTM) and EV/Revenue is 96.93, reflecting low sales and biotech development-stage economics. CompanyRating data dated 2026-03-30 shows an external rating of C- / Strong Sell, highlighting divergent views between market metrics and Meyka scenario analysis.

Catalysts, risks and what to watch

Primary catalysts are clinical and trial updates for ARCEX/ARCIM, any upward revision to cash runway, and commercial signals from the US. Key risks include continued negative margins, potential dilution given the EUR 14.82 million implied market cap relative to cash needs, and weak revenue traction. Watch management commentary on timing for pivotal studies, operating expense guidance, and milestone-linked partnerships or financing announcements. For market context, track Healthcare sector moves and biotech peer sentiment.

Outlook, scenarios and model forecasts

Meyka AI’s forecast model projects a 12-month price of EUR 4.06, a monthly target of EUR 3.17, and a three-year projection of EUR 3.18. Compared with the current price of EUR 3.315, the 12-month model implies an upside of +22.35% while the monthly projection implies -4.37%. Forecasts are model-based projections and not guarantees. Scenario price targets: Bear EUR 2.00, Base EUR 3.50, Bull EUR 5.75 — these reflect clinical progress, funding outcomes, and sector momentum. For live quotes and market context see Investing.com and our Meyka stock page for ONWD.BR: https://meyka.ai/stocks/ONWD.BR.

Final Thoughts

ONWD.BR stock trades at EUR 3.315 intraday on EURONEXT with heightened volatility ahead of the 31 Mar 2026 earnings release. Investors should focus on cash runway commentary, R&D cadence for ARCEX and ARCIM, and any changes to clinical timelines. Meyka AI’s forecast model projects a 12-month price of EUR 4.06, implying approximately +22.35% from the current EUR 3.315; the model also shows a nearer-term monthly projection of EUR 3.17, implying slightly lower near-term risk. Technicals are oversold, which can magnify reactions to positive surprises but also accelerate downside on negative news. Our Meyka grade (62.67, Grade B, HOLD) balances development upside against weak current financials, negative EPS and high valuation multiples. Active traders may use tight stops given ATR EUR 0.14, while longer-term investors should seek clear clinical progress or financing clarity before increasing exposure. Remember forecasts are model-based projections and not guarantees; use them as one input in portfolio decisions and consult the full filings and the company release for primary data. Meyka AI provides this as an AI-powered market analysis platform snapshot, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.